Company record · updated August 5, 2026
Carmot Therapeutics Inc.: 6 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs November 17, 2023 to November 17, 2023.
6observations
1source filings
6verified rows
2023-11-17most recent as-of date
Source rails for this company: S-1 charter round (6).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2023-11-17 | Series E price per share | 23.0083 USD | — | VERIFIED | "Original Issue Price" defined for Series E | 000119312523279847 |
| 2023-11-17 | Series D-1 price per share | 16.3098 USD | — | VERIFIED | "Original Issue Price" defined for Series D-1 | 000119312523279847 |
| 2023-11-17 | Series D price per share | 19.188 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312523279847 |
| 2023-11-17 | Series C price per share | 14.5808 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312523279847 |
| 2023-11-17 | Series B price per share | 6.3656 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312523279847 |
| 2023-11-17 | Series A price per share | 0.63 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312523279847 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.